Present and future in the treatment of diabetic Kidney Disease

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Quiroga, Borja ^a   Arroyo, David ^b   De Arriba, Gabriel ^c  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AST 120; BARDOXOLONE METHYL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PALOSURAN; PARICALCITOL; PENTOXIFYLLINE; PYRIDOXAMINE; RAPAMYCIN; SPIRONOLACTONE; SULODEXIDE; TRANSCRIPTION FACTOR; VITAMIN D RECEPTOR;

BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; WEIGHT REDUCTION; ALBUMINURIA; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84928573635     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/801348     Document Type: Review

References (170)

1. Centers for Disease Control and Prevention, Diabetes Report Card 2012, Department ofHealth and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2012, http://www. cdc. gov/diabetes/pubs/pdf/diabetesreportcard. pdf.
2. United States RenalData System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States, National Institutes ofHealth, National Institute ofDiabetes andDigestive and Kidney Diseases, Bethesda, Md, USA, 2014, http://www. usrds. org/2014/view/Default. aspx.
3. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030, " Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4-14, 2010.
4. A. X. Garg, B. A. Kiberd, W. F. Clark, R. B. Haynes, and C. M. Clase, "Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III, " Kidney International, vol. 61, no. 6, pp. 2165-2175, 2002.
5. R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman, and UKPDS Study Group, "Risk factors for renal dysfunction in type 2 diabetes: U. K. Prospective Diabetes Study 74, " Diabetes, vol. 55, no. 6, pp. 1832-1839, 2006.
6. M. E. Molitch, M. Steffes, W. Sun et al. , "Development and progression of renal insufficiencywith and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study, " Diabetes Care, vol. 33, no. 7, pp. 1536-1543, 2010.
7. A. S. Levey, D. Cattran, A. Friedman et al. , "Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration, " American Journal of Kidney Diseases, vol. 54, no. 2, pp. 205-226, 2009.
8. A. Thompson, "Proteinuria as a surrogate end point-more data are needed, " Nature Reviews Nephrology, vol. 8, no. 5, pp. 306-309, 2012.
9. G. L. Bakris, "Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus, " Mayo Clinic Proceedings, vol. 86, no. 5, pp. 444-456, 2011.
10. DCCT/EDIC Research Group, "Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial, " Kidney International, vol. 47, no. 6, pp. 1703-1720, 1995.
11. DCCT/EDIC Research Group, "Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The diabetes control and complications trial/epidemiology of diabetes interventions and complications research group, "The New England Journal ofMedicine, vol. 342, no. 6, pp. 381-389, 2000.
12. ADVANCE Collaborative Group, A. Patel, S. MacMahon et al. , "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, " The New England Journal of Medicine, vol. 358, no. 24, pp. 2560-2572, 2008.
13. The DCCT/EDIC Research Group, I. H. de Boer, W. Sun et al. , "Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes, "The New England Journal of Medicine, vol. 365, no. 25, pp. 2366-2376, 2011.
14. V. Perkovic, H. L. Heerspink, J. Chalmers et al. , "Intensive glucose control improves kidney outcomes in patients with type 2diabetes, " Kidney International, vol. 83, no. 3, pp. 517-523, 2013.
15. M. Daniels, S. N. Dubose, D. M. Maahs et al. , "Factors associated with microalbuminuria in 7, 549 children and adolescents with type 1 diabetes in the T1D exchange clinic registry, " Diabetes Care, vol. 36, no. 9, pp. 2639-2645, 2013.
16. I. H. de Boer and DCCT/EDIC Research Group, "Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study, " Diabetes Care, vol. 37, no. 1, pp. 24-30, 2014.
17. American Diabetes Association, "Standards of medical care in diabetes-2015, " Diabetes Care, vol. 38, supplement 1, pp. S4-S93, 2015.
18. KDOQI, "KDOQI clinical practice guideline for diabetes and CKD: 2012 update, " American Journal of Kidney Diseases, vol. 60, no. 5, pp. 850-886, 2012.
19. P.-H. Groop, M. E. Cooper, V. Perkovic, A. Emser, H.-J. Woerle, and M. von Eynatten, "Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction, " Diabetes Care, vol. 36, no. 11, pp. 3460-3468, 2013.
20. H. Fujita, H. Taniai, H. Murayama et al. , "DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1 in type 2 diabetic patients with incipient nephropathy, " Endocrine Journal, vol. 61, no. 2, pp. 159-166, 2014.
21. M. Daniels, S. N. DuBose, D. M. Maahs et al. , "KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, " American Journal of Kidney Diseases, vol. 49, supplement 2, no. 2, pp. S12-S154, 2007.
22. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group, "KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease, " Kidney International Supplements, vol. 2, pp. 337-414, 2012.
23. W. C. Cushman, G. W. Evans, R. P. Byington et al. , "Effects of intensive blood-pressure control in type 2 diabetes mellitus, " The New England Journal of Medicine, vol. 362, no. 17, pp. 1575-1585, 2010.
24. H. Haller, S. Ito, J. L. Izzo Jr. et al. , "Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes, " The New England Journal of Medicine, vol. 364, no. 10, pp. 907-917, 2011.
25. G. Eknoyan, "Obesity, diabetes, and chronic kidney disease, " Current Diabetes Reports, vol. 7, no. 6, pp. 449-453, 2007.
26. J. F. Briffa, A. J. Mcainch, P. Poronnik, and D. H. Hryciw, "Adipokines as a link between obesity and chronic kidney disease, " The American Journal of Physiology-Renal Physiology, vol. 305, no. 12, pp. F1629-F1636, 2013.
27. M. C. E. Rossi, A. Nicolucci, F. Pellegrini et al. , "Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND Study, " Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 2, pp. 110-116, 2010.
28. A. N. Friedman, M. Chambers, L. M. Kamendulis, and J. Temmerman, "Short-term changes after a weight reduction intervention in advanced diabetic nephropathy, " Clinical Journal of theAmericanSociety of Nephrology, vol. 8, no. 11, pp. 1892-1898, 2013.
29. E. Morales, M. A. Valero, M. León, E. Hernández, andM. Praga, "Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies, "AmericanJournal of Kidney Diseases, vol. 41, no. 2, pp. 319-327, 2003.
30. K. J. Neff, A. H. Frankel, F. W. K. Tam, D. M. Sadlier, C. Godson, and C. W. le Roux, "The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation, " Nephrology Dialysis Transplantation, vol. 28, supplement 4, pp. 73-82, 2013.
31. B. L. Kasiske, J. D. A. Lakatua, J. Z. Ma, and T. A. Louis, "A metaanalysis of the effects of dietary protein restriction on the rate of decline in renal function, " American Journal of Kidney Diseases, vol. 31, no. 6, pp. 954-961, 1998.
32. L. T. J. Pijls, H. de Vries, A. J. M. Donker, and J. T. M. van Eijk, "The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial, " Nephrology Dialysis Transplantation, vol. 14, no. 6, pp. 1445-1453, 1999.
33. H. P. Hansen, E. Tauber-Lassen, B. R. Jensen, and H.-H. Parving, "Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy, " Kidney International, vol. 62, no. 1, pp. 220-228, 2002.
34. M. Cignarelli, O. Lamacchia, S. di Paolo, and L. Gesualdo, "Cigarette smoking and kidney dysfunction in diabetes mellitus, " Journal of Nephrology, vol. 21, no. 2, pp. 180-189, 2008.
35. T. Chuahirun, J. Simoni, C. Hudson et al. , "Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes, " American Journal of theMedical Sciences, vol. 327, no. 2, pp. 57-67, 2004.
36. K. Phisitkul, K. Hegazy, T. Chuahirun et al. , "Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy, " The American Journal of the Medical Sciences, vol. 335, no. 4, pp. 284-291, 2008.
37. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al. , "Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL, " Kidney International, vol. 65, no. 6, pp. 2309-2320, 2004.
38. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al. , "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, " The New England Journal of Medicine, vol. 345, no. 12, pp. 851-860, 2001.
39. G. Viberti, C. E. Mogensen, L. C. Groop, andJ. F. Pauls, "Effectof captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. EuropeanMicroalbuminuriaCaptopril StudyGroup, " Journal of the American Medical Association, vol. 271, no. 4, pp. 275-279, 1994.
40. L. M. B. Laffel, J. B. McGill, and D. J. Gans, "The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria, " The American Journal of Medicine, vol. 99, no. 5, pp. 497-504, 1995.
41. L. F. Fried, N. Emanuele, J. H. Zhang et al. , "Combined angiotensin inhibition for the treatment of diabetic nephropathy, " The New England Journal of Medicine, vol. 369, no. 20, pp. 1892-1903, 2013.
42. G. Fernandez Juarez, J. Luño, V. Barrio et al. , "Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial, " American Journal of Kidney Diseases, vol. 61, no. 2, pp. 211-218, 2013.
43. ONTARGET Investigators, S. Yusuf, K. K. Teo et al. , "Telmisartan, ramipril, or both in patients at high risk for vascular events, " The New England Journal of Medicine, vol. 358, no. 15, pp. 1547-1559, 2008.
44. L. Tylicki, A. Jakubowska, S. Lizakowski, D. Swietlik, and B. Rutkowski, "Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study, " Journal of the Renin-Angiotensin-Aldosterone System, 2014.
45. H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al. , "Cardiorenal end points in a trial of aliskiren for type 2 diabetes, " The New England Journal ofMedicine, vol. 367, no. 23, pp. 2204-2213, 2012.
46. H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, andN. K. Hollenberg, "Aliskiren combined with losartan in type 2 diabetes and nephropathy, " The New England Journal of Medicine, vol. 358, no. 23, pp. 2433-2446, 2008.
47. A. Sato, K. Hayashi, M. Naruse, and T. Saruta, "Effectiveness of aldosterone blockade in patients with diabetic nephropathy, " Hypertension, vol. 41, no. 1, pp. 64-68, 2003.
48. A. Esteghamati, S. Noshad, S. Jarrah, M. Mousavizadeh, S. H. Khoee, and M. Nakhjavani, "Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial, "NephrologyDialysis Transplantation, vol. 28, no. 11, pp. 2823-2833, 2013.
49. M. Epstein, G. H. Williams, M. Weinberger et al. , "Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes, " Clinical journal of the American Society of Nephrology, vol. 1, no. 5, pp. 940-951, 2006.
50. P. Susantitaphong, K. Sewaralthahab, E. M. Balk, S. Eiam-Ong, N. E. Madias, and B. L. Jaber, "Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis, " American Journal of Hypertension, vol. 26, no. 3, pp. 424-441, 2013.
51. F. F. Hou, D. Xie, X. Zhang et al. , "Renoprotection of Optimal AntiproteinuricDoses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency, " Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1889-1898, 2007.
52. P. Ruggenenti, A. Fassi, A. P. Ilieva et al. , "Preventingmicroalbuminuria in type 2 diabetes, " The New England Journal of Medicine, vol. 351, no. 19, pp. 1941-1951, 2004.
53. J. Lv, V. Perkovic, C. V. Foote, M. E. Craig, J. C. Craig, and G. F. M. Strippoli, "Antihypertensive agents for preventing diabetic kidney disease. , " Cochrane Database of Systematic Reviews, no. 12, Article ID CD004136, 2012.
54. M. G. Saklayen, L. K. Gyebi, J. Tasosa, and J. Yap, "Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial, " Journal of Investigative Medicine, vol. 56, no. 4, pp. 714-719, 2008.
55. M. B. Davidson, A. Wong, A. H. Hamrahian, M. Stevens, and E. S. Siraj, "Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensinconverting enzyme inhibitors, " Endocrine Practice, vol. 14, no. 8, pp. 985-992, 2008.
56. U. F. Mehdi, B. Adams-Huet, P. Raskin, G. L. Vega, and R. D. Toto, "Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2641-2650, 2009.
57. S. Bianchi, R. Bigazzi, and V. M. Campese, "Long-termeffects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease, " Kidney International, vol. 70, no. 12, pp. 2116-2123, 2006.
58. E. Morales, V. G. Millet, J. Rojas-Rivera et al. , "Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases, " Nephrology Dialysis Transplantation, vol. 28, no. 2, pp. 405-412, 2013.
59. B. Pitt, F. Zannad, W. J. Remme et al. , "The effect of spironolactone on morbidity and mortality in patients with severe heart failure, " The New England Journal of Medicine, vol. 341, no. 10, pp. 709-717, 1999.
60. B. Fernandez-Fernandez, A. Ortiz, C. Gomez-Guerrero, and J. Egido, "Therapeutic approaches to diabetic nephropathy-beyond the RAS, " Nature Reviews Nephrology, vol. 10, no. 6, pp. 325-346, 2014.
61. H. Zheng, S. A. Whitman, W. Wu et al. , "Therapeutic potential ofNrf2 activators in streptozotocin-induced diabetic nephropathy, " Diabetes, vol. 60, no. 11, pp. 3055-3066, 2011.
62. K. Yoh, A. Hirayama, K. Ishizaki et al. , "Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice, " Genes to Cells, vol. 13, no. 11, pp. 1159-1170, 2008.
63. P. E. Pergola, P. Raskin, R. D. Toto et al. , "Bardoxolone methyl and kidney function in CKD with type 2 diabetes, " The New England Journal of Medicine, vol. 365, no. 4, pp. 327-336, 2011.
64. D. de Zeeuw, T. Akizawa, P. Audhya et al. , "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, " The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.
65. S. M. Tan, A. Sharma, N. Stefanovic et al. , "Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease, " Diabetes, vol. 63, no. 9, pp. 3091-3103, 2014.
66. G. Fernández-Juárez, J. Luño, V. Barrio et al. , "25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system, " Clinical Journal of the American Society of Nephrology, vol. 8, no. 11, pp. 1870-1876, 2013.
67. D. L. Andress, "Vitamin D in chronic kidney disease: a systemic role for selective vitaminDreceptor activation, " Kidney International, vol. 69, no. 1, pp. 33-43, 2006.
68. R. Agarwal, M. Acharya, J. Tian et al. , "Antiproteinuric effect of oral paricalcitol in chronic kidney disease, " Kidney International, vol. 68, no. 6, pp. 2823-2828, 2005.
69. D. de Zeeuw, R. Agarwal, M. Amdahl et al. , "Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial, " The Lancet, vol. 376, no. 9752, pp. 1543-1551, 2010.
70. H. J. Lambers Heerspink, R. Agarwal, D. W. Coyne et al. , "The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics, " The American Journal of Nephrology, vol. 30, no. 3, pp. 280-286, 2009.
71. Z. Eren, M. Y. Günal, E. A. Bakir et al. , "Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats, " Kidney and Blood Pressure Research, vol. 39, no. 6, pp. 581-590, 2014.
72. M. H. de Borst, R. Hajhosseiny, H. Tamez, J. Wenger, R. Thadhani, and D. J. A. Goldsmith, "Active vitamin D treatment for reduction of residual proteinuria: a systematic review, " Journal of theAmerican Society of Nephrology, vol. 24, no. 11, pp. 1863-1871, 2013.
73. N. K. Agrawal and S. Kant, "Targeting inflammation in diabetes: newer therapeutic options, " World Journal of Diabetes, vol. 5, no. 5, pp. 697-710, 2014.
74. M. Rodŕ?guez-Morán, G. González-González, M. V. Bermúdez-Barba et al. , "Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria-a double-blind, placebo-controlled randomized trial, " Clinical Nephrology, vol. 66, no. 1, pp. 3-10, 2006.
75. J. F. Navarro-González, C. Mora-Fernández, M. Muros de Fuentes et al. , "Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial, " Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 220-229, 2015.
76. M. Goicoechea, S. G. de Vinuesa, B. Quiroga et al. , "Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial, " Journal of Nephrology, vol. 25, no. 6, pp. 969-975, 2012.
77. F. P. Brouwers, F. W. Asselbergs, H. L. Hillege et al. , "Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT), "The American Heart Journal, vol. 161, no. 6, pp. 1171-1178, 2011.
78. S. J. Shah, D. D. Waters, P. Barter et al. , "Intensive lipidlowering with atorvastatin for secondaryprevention in patients after coronary artery bypass surgery, " Journal of the American College of Cardiology, vol. 51, no. 20, pp. 1938-1943, 2008.
79. W. Lieberthal and J. S. Levine, "The role of the mammalian target of rapamycin (mTOR) in renal disease, " Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2493-2502, 2009.
80. A. H. Hopper, H. Tindall, and J. A. Davies, "Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy, " Nephrology Dialysis Transplantation, vol. 4, no. 2, pp. 140-143, 1989.
81. J. Rodriguez-Vita, M. Ruiz-Ortega, M. Rupérez et al. , "Endothelin-1, via ETA receptor and independently of transforming growth factor-, increases the connective tissue growth factor in vascular smooth muscle cells, " Circulation Research, vol. 97, no. 2, pp. 125-134, 2005.
82. D. E. Kohan and D. M. Pollock, "Endothelin antagonists for diabetic and non-diabetic chronic kidney disease, " British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 573-579, 2013.
83. D. Gómez-Garre, R. Largo, X.-H. Liu et al. , "An orally active ET/ET receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis, " Kidney International, vol. 50, no. 3, pp. 962-972, 1996.
84. D. E. Kohan, J. G. Cleland, L. J. Rubin, D. Theodorescu, and M. Barton, "Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?" Life Sciences, vol. 91, no. 13-14, pp. 528-539, 2012.
85. J. F. E. Mann, D. Green, K. Jamerson et al. , "Avosentan for overt diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 527-535, 2010.
86. D. L. Andress, B. Coll, Y. Pritchett, J. Brennan, M. Molitch, and D. E. Kohan, "Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD), " Life Sciences, vol. 91, no. 13-14, pp. 739-742, 2012.
87. K. Winiarska, K. Szymanski, P. Gorniak, M. Dudziak, and J. Bryla, "Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits, " Biochimie, vol. 91, no. 2, pp. 261-270, 2009.
88. G. G. Wang, X. H. Lu, W. Li, X. Zhao, andC. Zhang, "Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats, " Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 323171, 7 pages, 2011.
89. S. Bhattacharya, P. Manna, R. Gachhui, and P. C. Sil, "DSaccharic acid 1, 4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines viaNF-B andPKCsignaling, " Toxicology and Applied Pharmacology, vol. 267, no. 1, pp. 16-29, 2013.
90. K. Khazim, Y. Gorin, R. C. Cavaglieri, H. E. Abboud, and P. Fanti, "The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo, " American Journal of Physiology-Renal Physiology, vol. 305, no. 5, pp. F691-F700, 2013.
91. J. F. Ndisang and A. Jadhav, "Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis, " Endocrinology, vol. 155, no. 1, pp. 215-229, 2014.
92. Z. Sun, Q. Fu, L. Cao, W. Jin, L. Cheng, and Z. Li, "Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials, " PLoS ONE, vol. 8, no. 1, Article ID e55124, 2013.
93. M. K. Fallahzadeh, B. Dormanesh, M. M. Sagheb et al. , "Effect of addition of silymarin to renin-angiotensin systeminhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial, " American Journal of Kidney Diseases, vol. 60, no. 6, pp. 896-903, 2012.
94. S. R. Hashemi, H. Noshad, A. Tabrizi et al. , "Angiotensin receptor blocker andN-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetesmellitus, " Iranian Journal of Kidney Diseases, vol. 6, no. 1, pp. 39-43, 2012.
95. K. Endo, A. Saiki, T. Yamaguchi et al. , "Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunctionrelated death in diabetic nephropathy patients: Sakura Study, " Journal ofAtherosclerosis andThrombosis, vol. 20, no. 5, pp. 494-502, 2013.
96. Y.-P. Siu, K.-T. Leung, M. K.-H. Tong, and T.-H. Kwan, "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level, " American Journal of Kidney Diseases, vol. 47, no. 1, pp. 51-59, 2006.
97. M. Goicoechea, S. G. de Vinuesa, U. Verdalles et al. , "Effect of allopurinol in chronic kidney disease progression and cardiovascular risk, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1388-1393, 2010.
98. D. M. Maahs, L. Caramori, D. Z. I. Cherney et al. , "Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study, " Current Diabetes Reports, vol. 13, no. 4, pp. 550-559, 2013.
99. T. Hosoya, K. Kimura, S. Itoh et al. , "The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study, " Trials, vol. 15, no. 1, article 26, 2014.
100. S. Budhiraja and J. Singh, "Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications, " Fundamental and Clinical Pharmacology, vol. 22, no. 3, pp. 231-240, 2008.
101. D. Bansal, Y. Badhan, K. Gudala, and F. Schifano, "Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials, " Diabetes & Metabolism Journal, vol. 37, no. 5, pp. 375-384, 2013.
102. M. J. Sheetz, L. P. Aiello, M. D. Davis et al. , "The effect of the Oral PKC inhibitor ruboxistaurin on vision loss in two phase 3 studies, " Investigative Ophthalmology and Visual Science, vol. 54, no. 3, pp. 1750-1757, 2013.
103. K. R. Tuttle, J. B. McGill, D. J. Haney, T. E. Lin, and P. W. Anderson, "Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease, " Clinical Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 631-636, 2007.
104. K. R. Tuttle, G. L. Bakris, R. D. Toto, J. B. McGill, K. Hu, and P. W. Anderson, "The effect of ruboxistaurin on nephropathy in type 2 diabetes, " Diabetes Care, vol. 28, no. 11, pp. 2686-2690, 2005.
105. K. R. Tuttle, J. B. McGill, E. J. Bastyr III, K. K. Poi, N. Shahri, and P. W. Anderson, "Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial, " American Journal of Kidney Diseases, vol. 65, no. 4, pp. 634-636, 2015.
106. M. Lassila, K. Jandeleit-Dahm, K. K. Seah et al. , "Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice, " Journal of theAmerican Society of Nephrology, vol. 16, no. 2, pp. 367-373, 2005.
107. M. Iyoda, T. Shibata, Y. Hirai, Y. Kuno, and T. Akizawa, "Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease, " Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1486-1496, 2011.
108. M. J. Kim and Y. Lim, "Protective effect of short-term genistein supplementation on the early stage in diabetes-induced renal damage, " Mediators of Inflammation, vol. 2013, Article ID 510212, 14 pages, 2013.
109. K. Taniguchi, L. Xia, H. J. Goldberg et al. , "Inhibition of src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice, " Diabetes, vol. 62, no. 11, pp. 3874-3886, 2013.
110. V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh, "Targeting of RhoA/ROCKsignalingameliorates progression of diabetic nephropathy independent of glucose control, " Diabetes, vol. 57, no. 3, pp. 714-723, 2008.
111. R. Komers, "Rho kinase inhibition in diabetic kidney disease, " British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 551-559, 2013.
112. L. Gu, Q. Gao, L. Ni, M. Wang, and F. Shen, "Fasudil inhibits epithelial-myofibroblast transdifferentiation of human renal tubular epithelialHK-2 cells induced by high glucose, " Chemical and Pharmaceutical Bulletin, vol. 61, no. 7, pp. 688-694, 2013.
113. D.-S. Jung, J. J. Li, S.-J. Kwak et al. , "FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells, " American Journal of Physiology-Renal Physiology, vol. 295, no. 2, pp. F595-F604, 2008.
114. N. Sugiyama, M. Kohno, and T. Yokoyama, "Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model, " Nephrology Dialysis Transplantation, vol. 27, no. 4, pp. 1351-1358, 2012.
115. S.-H. Kim, Y.-W. Jang, P. Hwang, H.-J. Kim, G.-Y. Han, and C.-W. Kim, "The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats, " Experimental and Molecular Medicine, vol. 44, no. 1, pp. 45-51, 2012.
116. C. A. Durand, M. J. Richer, K. Brenker et al. , "Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice, " Autoimmunity, vol. 46, no. 1, pp. 62-73, 2013.
117. I. I. Shemesh, B. Rozen-Zvi, Y. Kalechman, U. Gafter, B. Sredni, and G. Drossopoulou, "AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway, " PLoS ONE, vol. 9, no. 12, 2014.
118. H. Sugimoto, V. S. LeBleu, D. Bosukonda et al. , "Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis, " Nature Medicine, vol. 18, no. 3, pp. 396-404, 2012.
119. F. C. Brosius III and J. C. He, "JAK inhibition and progressive kidney disease, " Current Opinion in Nephrology and Hypertension, vol. 24, no. 1, pp. 88-95, 2015.
120. G. Ortiz-Muñoz, V. Lopez-Parra, O. Lopez-Franco et al. , "Suppressors of cytokine signaling abrogate diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 21, no. 5, pp. 763-772, 2010.
121. M.-L. P. Gross, A. Koch, B. Mühlbauer et al. , "Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes, " Laboratory Investigation, vol. 86, no. 3, pp. 262-274, 2006.
122. T. Takahashi, M. Yano, J. Minami et al. , "Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy, " Diabetes Research and Clinical Practice, vol. 58, no. 2, pp. 123-129, 2002.
123. S. Ogawa, T. Mori, K. Nako, T. Ishizuka, and S. Ito, "Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes, " Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 362-368, 2008.
124. J. A. Tumlin, C. M. Galphin, and B. H. Rovin, "Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1, " Journal of Diabetes Research, vol. 2013, Article ID 489869, 8 pages, 2013.
125. R. T. Day, R. C. Cavaglieri, and D. Feliers, "Apelin retards the progression of diabetic nephropathy, " The American Journal of Physiology-Renal Physiology, vol. 304, no. 6, pp. F788-F800, 2013.
126. H. Chen, J. Li, L. Jiao et al. , "Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse, " The Journal of Physiology, vol. 592, part 3, pp. 505-521, 2014.
127. P. Gil-Bernabe, C. N. D'Alessandro-Gabazza, M. Toda et al. , "Exogenous activated protein C inhibits the progression of diabetic nephropathy, " Journal of Thrombosis and Haemostasis, vol. 10, no. 3, pp. 337-346, 2012.
128. F. Barutta, F. Piscitelli, S. Pinach et al. , "Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy, " Diabetes, vol. 60, no. 9, pp. 2386-2396, 2011.
129. D. H. Nam, M. H. Lee, J. E. Kimet al. , "Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice, " Endocrinology, vol. 153, no. 3, pp. 1387-1396, 2012.
130. A. Doria, M. A. Niewczas, and P. Fiorina, "Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?" Seminars in Nephrology, vol. 32, no. 5, pp. 437-444, 2012.
131. Y. Moriwaki, T. Inokuchi, A. Yamamoto et al. , "Effect of TNFalpha inhibition on urinary albumin excretion in experimental diabetic rats, " Acta Diabetologica, vol. 44, no. 4, pp. 215-218, 2007.
132. K. Omote, T. Gohda, M. Murakoshi et al. , "Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice, " The American Journal of Physiology-Renal Physiology, vol. 306, no. 11, pp. F1335-F1347, 2014.
133. K. Sharma, J. H. Ix, A. V. Mathewet al. , "Pirfenidone for diabetic nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 22, no. 6, pp. 1144-1151, 2011.
134. H. Akahori, T. Ota, M. Torita, H. Ando, S. Kaneko, and T. Takamura, "Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression, " Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 2, pp. 514-521, 2005.
135. J. Soma, K. Sato, H. Saito, and Y. Tsuchiya, "Effect of tranilast in early-stage diabetic nephropathy, " Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2795-2799, 2006.
136. F. N. Ziyadeh, "Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy, " Diabetes Research and Clinical Practice, vol. 82, supplement 1, pp. S38-S41, 2008.
137. H. Trachtman, F. C. Fervenza, D. S. Gipson et al. , "A phase 1, single-dose study of fresolimumab, an anti-TGF-antibody, in treatment-resistant primary focal segmental glomerulosclerosis, " Kidney International, vol. 79, no. 11, pp. 1236-1243, 2011.
138. H. S. Jeong, K. K. Park, S. P. Kim, I. J. Choi, I. K. Lee, and H. C. Kim, "Effect of antisense TGF-1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney, " Journal of Korean Medical Science, vol. 19, no. 3, pp. 374-383, 2004.
139. L. M. Russo, E. del Re, D. Brown, and H. Y. Lin, "Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor, " Diabetes, vol. 56, no. 2, pp. 380-388, 2007.
140. G. Castoldi, C. R. T. di Gioia, C. Bombardi et al. , "Renal antifibrotic effect of n-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats, "The American Journal of Nephrology, vol. 37, no. 1, pp. 64-73, 2013.
141. S. G. Adler, S. Schwartz, M. E. Williams et al. , "Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1420-1428, 2010.
142. J. A. Moreno, S. Moreno, A. Rubio-Navarro et al. , "Targeting chemokines in proteinuria-induced renal disease, " ExpertOpinion onTherapeutic Targets, vol. 16, no. 8, pp. 833-845, 2012.
143. M. Okamoto, M. Fuchigami, T. Suzuki, and N. Watanabe, "A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models, " Biological and Pharmaceutical Bulletin, vol. 35, no. 11, pp. 2069-2074, 2012.
144. S. J. Seok, E. S. Lee, G. T. Kim et al. , "Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice, " Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1700-1710, 2013.
145. T. Sullivan, Z. Miao, D. J. Dairaghi et al. , "CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice, " The American Journal of Physiology-Renal Physiology, vol. 305, no. 9, pp. F1288-F1297, 2013.
146. R. J. Tan andY. Liu, "Matrix metalloproteinases in kidney homeostasis and diseases, " The American Journal of Physiology-Renal Physiology, vol. 302, no. 11, pp. F1351-F1361, 2012.
147. H. K. Aggarwal, D. Jain, P. Talapatra, R. K. Yadav, T. Gupta, and K. L. Kathuria, "Evaluation of role of doxycycline (amatrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy, " Renal Failure, vol. 32, no. 8, pp. 941-946, 2010.
148. J. M. Williams, J. Zhang, P. North et al. , "Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy, " The American Journal of Physiology-Renal Physiology, vol. 300, no. 4, pp. F983-F998, 2011.
149. P. Trionfini, A. Benigni, and G. Remuzzi, "MicroRNAs in kidney physiology and disease, " Nature Reviews Nephrology, vol. 11, no. 1, pp. 23-33, 2014.
150. H. Wu, L. Kong, S. Zhou et al. , "The role of microRNAs in diabetic nephropathy, " Journal of Diabetes Research, vol. 2014, Article ID 920134, 12 pages, 2014.
151. S. Putta, L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan, "Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 458-469, 2012.
152. R. Ramasamy, S. F. Yan, and A. M. Schmidt, "The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes, " Vascular Pharmacology, vol. 57, no. 5-6, pp. 160-167, 2012.
153. A. I. Serban, L. Stanca, O. I. Geicu, M. C. Munteanu, M. Costache, and A. Dinischiotu, "Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-1 RAGE-1, " Journal of Diabetes, vol. 7, no. 1, pp. 114-124, 2015.
154. A. Flyvbjerg, L. Denner, B. F. Schrijvers et al. , "Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice, " Diabetes, vol. 53, no. 1, pp. 166-172, 2004.
155. J. H. Kim, C. O. Hong, Y. C. Koo, S. J. Kim, and K. W. Lee, "Oral administration of ethyl acetate-soluble portion of Terminalia chebula conferring protection from streptozotocininduced diabetic mellitus and its complications, " Biological and Pharmaceutical Bulletin, vol. 34, no. 11, pp. 1702-1709, 2011.
156. W. K. Bolton, D. C. Cattran, M. E. Williams et al. , "Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy, " American Journal of Nephrology, vol. 24, no. 1, pp. 32-40, 2004.
157. M. E. Williams, W. K. Bolton, R. G. Khalifah, T. P. Degenhardt, R. J. Schotzinger, and J. B. McGill, "Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy, " American Journal of Nephrology, vol. 27, no. 6, pp. 605-614, 2007.
158. E. J. Lewis, T. Greene, S. Spitalewiz et al. , "Pyridorin in type 2 diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 131-136, 2012.
159. G. Schulman, R. Vanholder, and T. Niwa, "AST-120 for themanagement of progression of chronic kidney disease, " International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 49-56, 2014.
160. T. Sanaka, T. Akizawa, K. Koide, and S. Koshikawa, "Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy, " Therapeutic Apheresis and Dialysis, vol. 8, no. 3, pp. 232-240, 2004.
161. K. Konishi, S. Nakano, S.-I. Tsuda, A. Nakagawa, T. Kigoshi, and D. Koya, "AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects, "Diabetes Research and Clinical Practice, vol. 81, no. 3, pp. 310-315, 2008.
162. G. Schulman, T. Berl, G. J. Beck et al. , "Randomized placebocontrolled EPPIC trials of AST-120 in CKD, " Journal of the American Society of Nephrology, 2014.
163. H. M. Wu, H. J. Sun, F. Wang, M. Yang, B. R. Dong, andG. J. Liu, "Oral adsorbents for preventing or delaying the progression of chronic kidney disease, " The Cochrane Database of Systematic Reviews, vol. 10, Article ID CD007861, 2014.
164. K. Eller, A. Kirsch, A. M. Wolf et al. , "Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy, " Diabetes, vol. 60, no. 11, pp. 2954-2962, 2011.
165. D. Zheng, Y. Wang, Q. Cao et al. , "Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus, " Nephron-Experimental Nephrology, vol. 118, no. 4, pp. e87-e99, 2011.
166. D. Patschan, K. Schwarze, E. Henze, J. U. Becker, S. Patschan, and G. A. Muller, "eEOC-mediated modulation of endothelial autophagy, senescence, and EnMT in murine diabetic nephropathy, " The American Journal of Physiology-Renal Physiology, vol. 307, no. 6, pp. F686-F694, 2014.
167. L. Vogt, C. Chiurchiu, H. Chadha-Boreham et al. , "Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy, " Hypertension, vol. 55, no. 5, pp. 1206-1209, 2010.
168. S. Yung, M. K. M. Chau, Q. Zhang, C. Z. Zhang, and T. M. Chan, "Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocininduced type I diabetic nephropathy, " PLoS ONE, vol. 8, no. 1, Article ID e54501, 2013.
169. E. J. Lewis, J. B. Lewis, T. Greene et al. , "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial, " American Journal of Kidney Diseases, vol. 58, no. 5, pp. 729-736, 2011.
170. D. K. Packham, R. Wolfe, A. T. Reutens et al. , "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 23, no. 1, pp. 123-130, 2012.